Alan Bernstein, President & CEO
Alan Bernstein became CIFAR’s President and Chief Executive Officer in May 2012.
Most recently, Dr. Alan Bernstein was executive director of the Global HIV Vaccine Enterprise in New York, an international alliance of researchers and funders charged with accelerating the search for an HIV vaccine. From 2000 to 2007, he served as the inaugural president of the Canadian Institutes of Health Research (CIHR), Canada’s federal agency for the support of health research. In that capacity, he led the transformation of health research in Canada.
After receiving his PhD from the University of Toronto, and following postdoctoral work at the Imperial Cancer Research Fund in London, Dr. Bernstein joined the Ontario Cancer Institute. In 1985, he joined the Samuel Lunenfeld Research Institute, was named its Associate Director in 1988 and served as Director of Research from 1994 to 2000.
Author of over 225 scientific publications, Dr. Bernstein has made extensive contributions to the study of stem cells, blood cell formation (hematopoiesis) and cancer. He chairs or is a member of advisory and review boards in Canada, the U.S., U.K., Italy and Australia. Dr. Bernstein also served as co-chair of the Scientific Advisory Committee for Stand Up 2 Cancer Canada with Phillip A. Sharp.
Dr. Bernstein has received numerous awards and honourary degrees for his contributions to science, including the 2008 Gairdner Wightman Award. In 2015, he was inducted into the Canadian Medical Hall of Fame. He is a Senior Fellow of Massey College, University of Toronto and, in 2002, was made an Officer of the Order of Canada.
Ideas Related to Alan Bernstein, President & CEO
CIFAR President & CEO Dr. Alan Bernstein is among 23 new appointees to the Order of Ontario, announced on Monday....
Great science starts with asking the right question. For more than three decades, CIFAR has been dedicated to connecting the...
Much of the Naylor report discussion has focussed on funding. But Canada also needs to overhaul its fundamental research enterprise...
Opinion: Much of the Naylor report discussion has focussed on funding. But Canada also needs to overhaul its fundamental research enterprise